SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Hepatitis and Tuberculosis
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
13 of
13
|
Simultaneous Initiation in ART-Naive PWH of DTG-Based ART & 3HP Maintains Efficacious DTG Levels (ABSTRACT
156)
Ethel D. Weld
The Johns Hopkins University, Baltimore, MD, USA
Early Bactericidal Activity of the Alpibectir-Ethionamide (AlpE) Combination Against Tuberculosis (ABSTRACT
157)
Jeantelle Du Preez
TASK Applied Science, Cape Town, South Africa
NAFLD and Advanced Fibrosis Are Common in Adults With HIV and Associated With Unique Histology (ABSTRACT
158)
Jennifer C. Price
University of California San Francisco, San Francisco, CA, USA
Semaglutide Reduces Metabolic-Associated Steatotic Liver Disease in People With HIV: The SLIM LIVER (ABSTRACT
159)
Jordan E. Lake
University of Texas at Houston, Houston, TX, USA
QUESTIONS AND ANSWERS (Part 1)
Trends in HIV and HCV Prevention Efforts and Incidence Among People Who Inject Drugs in Baltimore (ABSTRACT
160)
Eshan U. Patel
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Preclinical Pharmacokinetic Assessment of a Hepatitis C Virus Long-Acting Injectable Formulation (ABSTRACT
161)
Usman Arshad
University of Liverpool, Liverpool, UK
Intrahepatic HDV Activity Is Fueled by Integrated HBV DNA-Derived HBs Independently From cccDNA Size (ABSTRACT
162)
Stefano D'Anna
University of Rome Tor Vergata, Rome, Italy
A 4-Month Regimen of Quabodepistat, Delamanid, and Bedaquiline for Pulmonary TB: Interim Results (ABSTRACT
163)
Simbarashe Takuva
Otsuka Novel Products GmbH
Provisional Results From a 3-month Clofazimine/Rifapentine-Containing Regimen for Drug-Sensitive TB (ABSTRACT
164)
John Metcalfe
University of California, San Francisco
QUESTIONS AND ANSWERS (Part 2)
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
13 of
13
|
